CoChat

Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms9692

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview schematic of intravital nanoparticle imaging for pharmacokinetic and pharmacodynamic analysis. Nanoparticles (a) were injected by tail-vein catheter and imaged in real time within the tumour using a dorsal window chamber (b). Imaging results enable simultaneous monitoring of circulating pharmacokinetics within the TMV (c, top); single-cell uptake of the nanoparticle vehicle and its drug payload (c, middle); and DNA damage response in tumour cells, monitored by 53BP1 puncta formation (c, bottom).
Figure 1 Overview schematic of intravital nanoparticle imaging for pharmacokinetic and pharmacodynamic analysis. Nanoparticles (a) were injected by tail-vein catheter and imaged in real time within the tumour using a dorsal window chamber (b). Imaging results enable simultaneous monitoring of circulating pharmacokinetics within the TMV (c, top); single-cell uptake of the nanoparticle vehicle and its drug payload (c, middle); and DNA damage response in tumour cells, monitored by 53BP1 puncta formation (c, bottom).CC BY · PubMed Central
Figure 2 Pharmacokinetic analysis of nanoparticle shows extended microvasculature half-life and heterogeneous tissue accumulation. (a) Nanoparticle concentrations are monitored (a) and quantified (b) using time-lapse confocal fluorescence microscopy in the dorsal window chamber model. Nanoencapsulation extends the TMV half-life to 55 min, a >5-fold increase compared with unencapsulated Pt(II) compounds in the same animal model29. Scale bar, 50 μm. Thick lines and shading denote means±s.e.m. (n=6).
Figure 2 Pharmacokinetic analysis of nanoparticle shows extended microvasculature half-life and heterogeneous tissue accumulation. (a) Nanoparticle concentrations are monitored (a) and quantified (b) using time-lapse confocal fluorescence microscopy in the dorsal window chamber model. Nanoencapsulation extends the TMV half-life to 55 min, a >5-fold increase compared with unencapsulated Pt(II) compounds in the same animal model29. Scale bar, 50 μm. Thick lines and shading denote means±s.e.m. (n=6).CC BY · PubMed Central
Figure 3 TNP causes mitotic arrest and DNA damage in a spatially defined dose-dependent manner. (a) Example images of 53BP1 puncta, 24 h post treatment with 1 mg kg−1 TNP, scale bar, 10 μm. (b) TNP treatment increases the fraction of cells exhibiting many 53BP1 puncta, measured across n≥3 animals and n>2,000 cells (*P<0.01, two-tailed t-test). Positive control (Pos. ctrl): 24 h supra-therapeutic cisplatin, 9 mg kg−1. (c) Heterogeneous local TNP vehicle and payload accumulation within 5 μm of single-cell nuclei correlate with corresponding DNA damage response in those cells (one-way analysis of variance; n>6,000 cells across n=5 animals; P<10−21 for both vehicle and payload); the local TNP payload correlates better with response compared with TNP vehicle (*P<0.05; two-tailed t-test). (d) Cell division events were quantified from time-lapse movies across n>1,000 cells (*P=0.001; two-tailed t-test; n=3 animals). All dosages in mg of Pt. Data are means±s.e.m. Neg ctrl, negative control.
Figure 3 TNP causes mitotic arrest and DNA damage in a spatially defined dose-dependent manner. (a) Example images of 53BP1 puncta, 24 h post treatment with 1 mg kg−1 TNP, scale bar, 10 μm. (b) TNP treatment increases the fraction of cells exhibiting many 53BP1 puncta, measured across n≥3 animals and n>2,000 cells (*P<0.01, two-tailed t-test). Positive control (Pos. ctrl): 24 h supra-therapeutic cisplatin, 9 mg kg−1. (c) Heterogeneous local TNP vehicle and payload accumulation within 5 μm of single-cell nuclei correlate with corresponding DNA damage response in those cells (one-way analysis of variance; n>6,000 cells across n=5 animals; P<10−21 for both vehicle and payload); the local TNP payload correlates better with response compared with TNP vehicle (*P<0.05; two-tailed t-test). (d) Cell division events were quantified from time-lapse movies across n>1,000 cells (*P=0.001; two-tailed t-test; n=3 animals). All dosages in mg of Pt. Data are means±s.e.m. Neg ctrl, negative control.CC BY · PubMed Central
Figure 4 Local TNP payload accumulation correlates with DNA damage in OVCA. (a) Single-cell DNA damage response correlates with local TNP payload levels in a model of disseminated metastatic OVCA. A2780CP OVCA cells were injected intraperitoneally; 6 weeks later, TNP was i.v. injected, and the following day intraperitoneal lesions were excised and imaged for DNA damage response (using 53BP1 puncta) and TNP uptake. Scale bar, 50 μm. (b) OVCA cells exhibiting detectable DNA damage by 53BP1-puncta have higher TNP payload levels, compared with those without (two-tailed t-test; s.e.m. across n=3 animals).
Figure 4 Local TNP payload accumulation correlates with DNA damage in OVCA. (a) Single-cell DNA damage response correlates with local TNP payload levels in a model of disseminated metastatic OVCA. A2780CP OVCA cells were injected intraperitoneally; 6 weeks later, TNP was i.v. injected, and the following day intraperitoneal lesions were excised and imaged for DNA damage response (using 53BP1 puncta) and TNP uptake. Scale bar, 50 μm. (b) OVCA cells exhibiting detectable DNA damage by 53BP1-puncta have higher TNP payload levels, compared with those without (two-tailed t-test; s.e.m. across n=3 animals).CC BY · PubMed Central
Figure 5 TNPs primarily accumulate in tumour cells and tumour-associated macrophages in steady state. (a) Intravital imaging of subcutaneous HT1080–53BP1-mApple tumours 24 h post injection with TNP (payload shown in yellow). TAMs (white) were labelled by dextran-coated nanoparticles injected 24 h prior. Scale bar, 100 μm. (b) Single-cell suspensions of the bulk tumour mass were immunostained and gated into various cell-populations, quantified here as fractions of the total number of cells analysed. (c) Macrophages accumulate the most TNP per cell. Using flow cytometry, uptake of both the TNP vehicle and its payload were quantified by fluorescence for each of the cell populations shown in b, 24 h post injection. CD45− host cells, neutrophils and ‘other’ CD45+ leukocytes did not accumulate significant TNP vehicle or payload. Fluorescence values normalized to the average macrophage values, after subtracting background autofluorescence of each cell population measured from control-treated tumours. (d) Most TNP accumulates in tumour cells and macrophages within the bulk tumour mass. TNP uptake measurements from c were weighted against the relative prevalence of each cell population in b to calculate the total fraction of TNP uptake within each cell population. For b–d, error bars denote standard error (n≥4).
Figure 5 TNPs primarily accumulate in tumour cells and tumour-associated macrophages in steady state. (a) Intravital imaging of subcutaneous HT1080–53BP1-mApple tumours 24 h post injection with TNP (payload shown in yellow). TAMs (white) were labelled by dextran-coated nanoparticles injected 24 h prior. Scale bar, 100 μm. (b) Single-cell suspensions of the bulk tumour mass were immunostained and gated into various cell-populations, quantified here as fractions of the total number of cells analysed. (c) Macrophages accumulate the most TNP per cell. Using flow cytometry, uptake of both the TNP vehicle and its payload were quantified by fluorescence for each of the cell populations shown in b, 24 h post injection. CD45− host cells, neutrophils and ‘other’ CD45+ leukocytes did not accumulate significant TNP vehicle or payload. Fluorescence values normalized to the average macrophage values, after subtracting background autofluorescence of each cell population measured from control-treated tumours. (d) Most TNP accumulates in tumour cells and macrophages within the bulk tumour mass. TNP uptake measurements from c were weighted against the relative prevalence of each cell population in b to calculate the total fraction of TNP uptake within each cell population. For b–d, error bars denote standard error (n≥4).CC BY · PubMed Central
Figure 6 Tumour-associated CX3CR1+ and F4/80+ host phagocytes accumulate TNP vehicle in a syngeneic model of lung cancer. Kras mutant p53−/− (KP) lung cancer cells were subcutaneously implanted into Cx3cr1GFP/+ reporter mice for directly visualizing GFP+ monocytes, dendritic cells and TAMs. Tumour-adjacent stromal regions were imaged 24 h following i.v. injection with TNP vehicle. Reporter mice expressed membrane-anchored tdTomato in all host cells, most visibly here with endothelium. Scale bar, 50 μm. (b) Fluorescence intensities of GFP and TNP vehicle were quantified across single-cells based on a, showing most stromal cells that accumulate TNP vehicle were also GFP+ (n=4 animals, n=250 cells). (c) Histological analysis of F4/80+ host phagocytes, 24 h post injection with TNP vehicle. Immunohistochemistry (left) shows tumours stained with haematoxylin and F4/80 (brown; scale bar, 100 μm), and corresponds with immunofluorescence (right) showing F4/80+ host phagocytes, EpCAM+ KP tumour cells, and local accumulation of TNP vehicle (scale bar, 25 μm). F4/80 labels a subset of GFP+ cells in Cx3cr1GFP/+ reporter mice38 (namely, macrophages).
Figure 6 Tumour-associated CX3CR1+ and F4/80+ host phagocytes accumulate TNP vehicle in a syngeneic model of lung cancer. Kras mutant p53−/− (KP) lung cancer cells were subcutaneously implanted into Cx3cr1GFP/+ reporter mice for directly visualizing GFP+ monocytes, dendritic cells and TAMs. Tumour-adjacent stromal regions were imaged 24 h following i.v. injection with TNP vehicle. Reporter mice expressed membrane-anchored tdTomato in all host cells, most visibly here with endothelium. Scale bar, 50 μm. (b) Fluorescence intensities of GFP and TNP vehicle were quantified across single-cells based on a, showing most stromal cells that accumulate TNP vehicle were also GFP+ (n=4 animals, n=250 cells). (c) Histological analysis of F4/80+ host phagocytes, 24 h post injection with TNP vehicle. Immunohistochemistry (left) shows tumours stained with haematoxylin and F4/80 (brown; scale bar, 100 μm), and corresponds with immunofluorescence (right) showing F4/80+ host phagocytes, EpCAM+ KP tumour cells, and local accumulation of TNP vehicle (scale bar, 25 μm). F4/80 labels a subset of GFP+ cells in Cx3cr1GFP/+ reporter mice38 (namely, macrophages).CC BY · PubMed Central
Figure 7 DNA-damaging TNP payload redistributes from TAMs to neighbouring tumour cells. (a) Compared with TAMs, tumour cells exhibit elevated TNP payload as a fraction of TNP vehicle (measured by flow-cytometry), suggesting payload redistribution (*P=0.005; two-tailed t-test; n≥4 per group). (b) Example immunofluorescence showing TNP vehicle uptake by F4/80+ macrophages and payload diffusion into surrounding tumour tissue. In lower left panel, red pseudo-colour indicates tumour cells with high levels of 53BP1 puncta. Of note, these cells are also adjacent to F4/80+ macrophages and contain elevated TNP payload. Scale bar, 50 μm. (c) By histological analysis, TNP payload but not vehicle is present at elevated levels within a 15-μm range of host phagocytes (*P=0.047, two-tailed t-test; n=3 animals). (d) By histological analysis, tumour cells immediately adjacent to F4/80+ macrophages exhibit elevated DNA damage response, compared with average DNA damage response seen in non-adjacent tumour cells for each of four animals shown by individual data points (*P=0.007; matched two-tailed t-test).
Figure 7 DNA-damaging TNP payload redistributes from TAMs to neighbouring tumour cells. (a) Compared with TAMs, tumour cells exhibit elevated TNP payload as a fraction of TNP vehicle (measured by flow-cytometry), suggesting payload redistribution (*P=0.005; two-tailed t-test; n≥4 per group). (b) Example immunofluorescence showing TNP vehicle uptake by F4/80+ macrophages and payload diffusion into surrounding tumour tissue. In lower left panel, red pseudo-colour indicates tumour cells with high levels of 53BP1 puncta. Of note, these cells are also adjacent to F4/80+ macrophages and contain elevated TNP payload. Scale bar, 50 μm. (c) By histological analysis, TNP payload but not vehicle is present at elevated levels within a 15-μm range of host phagocytes (*P=0.047, two-tailed t-test; n=3 animals). (d) By histological analysis, tumour cells immediately adjacent to F4/80+ macrophages exhibit elevated DNA damage response, compared with average DNA damage response seen in non-adjacent tumour cells for each of four animals shown by individual data points (*P=0.007; matched two-tailed t-test).CC BY · PubMed Central
Figure 8 Macrophage depletion reduces intratumoral accumulation and efficacy of TNP. (a) TNP reduces tumour growth in a macrophage-dependent manner. Animals were treated with TNP (green arrows) and clodronate liposomes (clod-lip; red arrows) to systemically deplete macrophages. Drug-free PLGA-PEG polymeric NPs and phosphate buffered saline liposomes (PBS-lip) were used as vehicle controls. TNP significantly reduced tumour growth (P=0.039), whereas clod-lip did not (P=0.21); however, clod-lip significantly reduced the impact of TNP (P=0.039 interaction term; all P-values used the two-tailed two-way analysis of variance, total n=38 animals). (b,c) Macrophage depletion using liposomal clodronate reduced the total amount (b) and concentration (c) of intratumoral Pt, measured using AAS (P=0.02 and P=0.03, respectively, two-tailed t-test; total n=22).
Figure 8 Macrophage depletion reduces intratumoral accumulation and efficacy of TNP. (a) TNP reduces tumour growth in a macrophage-dependent manner. Animals were treated with TNP (green arrows) and clodronate liposomes (clod-lip; red arrows) to systemically deplete macrophages. Drug-free PLGA-PEG polymeric NPs and phosphate buffered saline liposomes (PBS-lip) were used as vehicle controls. TNP significantly reduced tumour growth (P=0.039), whereas clod-lip did not (P=0.21); however, clod-lip significantly reduced the impact of TNP (P=0.039 interaction term; all P-values used the two-tailed two-way analysis of variance, total n=38 animals). (b,c) Macrophage depletion using liposomal clodronate reduced the total amount (b) and concentration (c) of intratumoral Pt, measured using AAS (P=0.02 and P=0.03, respectively, two-tailed t-test; total n=22).CC BY · PubMed Central
Figure 9 TNP delivery to the liver blocks development of micro-metastases. (a) Representative liver micro-metastasis, 2 weeks after i.v. injection of 4T1 breast cancer cells (haematoxylin and eosin staining of FFPE tissue section). (b) TNP reduces liver micro-metastasis development in the 4T1 model of haematogenous metastasis (two-tailed t-test; shown as mean±s.e.m.; n≥5). To initially deliver TNPs to host phagocytes (rather than tumour cells), TNPs were i.v. administered (1 mg kg−1) 6 h before i.v. injection of 4T1 cancer cells, such that TNP largely cleared the circulation at the time of cancer cell administration. One-third of the cohort received subsequent TNP treatments as indicated.
Figure 9 TNP delivery to the liver blocks development of micro-metastases. (a) Representative liver micro-metastasis, 2 weeks after i.v. injection of 4T1 breast cancer cells (haematoxylin and eosin staining of FFPE tissue section). (b) TNP reduces liver micro-metastasis development in the 4T1 model of haematogenous metastasis (two-tailed t-test; shown as mean±s.e.m.; n≥5). To initially deliver TNPs to host phagocytes (rather than tumour cells), TNPs were i.v. administered (1 mg kg−1) 6 h before i.v. injection of 4T1 cancer cells, such that TNP largely cleared the circulation at the time of cancer cell administration. One-third of the cohort received subsequent TNP treatments as indicated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 448

Metadata

Authors
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., Kolishetti, N., Pittet, M., Lippard, S. J., Farokhzad, O. C., & Weissleder, R.
Affiliations
  • Harvard University (US)
  • Massachusetts Institute of Technology (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Weissleder, Ralph
Venue
Nature Communications
Published
2015-10-27
Volume
6
Issue
1
Pages
8692-8692
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1874889006
Cited by
441
References
70
Citations by year
2026: 18 · 2025: 29 · 2024: 38 · 2023: 40 · 2022: 40 · 2021: 46 · 2020: 62 · 2019: 55 · 2018: 48 · 2017: 42 · 2016: 23
FWCI
13.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • Deutsche Forschungsgemeinschaft (PF809/1-1, CA034992)
  • National Institutes of Health (CA151884, U54-CA151884, CA034992, CA139980, PO1-CA139980)
  • National Cancer Institute (CA-034992, CA139980, P50CA086355, R01CA164448, U54CA151884, P01CA139980, R37CA034992, CA151884, R01CA034992, P30CA014051, T32CA079443)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
tumour-associated macrophages, nanotherapeutics, pharmacodynamics, single-cell imaging, DNA damage response, slow drug release, TAM depletion, nanoparticle accumulation, cancer nanomedicine
MeSH terms
Animals, Antineoplastic Agents, Female, Humans, Macrophages, Mice, Inbred C57BL, Mice, Nude, Neoplasms, Platinum, Prodrugs, Drug Delivery Systems, Cell Line, Tumor, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug. https://app.cochat.ai/papers/10.1038/ncomms9692
The paper
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., Kolishetti, N., Pittet, M., Lippard, S. J., Farokhzad, O. C., & Weissleder, R. (2015). Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug. Nature Communications. https://doi.org/10.1038/ncomms9692

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.